Literature DB >> 28704712

Multipurpose efficacy of ZnO nanoparticles coated by the crustacean immune molecule β-1, 3-glucan binding protein: Toxicity on HepG2 liver cancer cells and bacterial pathogens.

Arokiadhas Iswarya1, Baskaralingam Vaseeharan2, Mahalingam Anjugam1, Balasubramaniem Ashokkumar3, Marimuthu Govindarajan4, Naiyf S Alharbi5, Shine Kadaikunnan5, Jamal M Khaled5, Giovanni Benelli6.   

Abstract

The effective treatment of cancer and bacterial pathogens are two key challenges in modern nanomedicine. Here, zinc oxide nanoparticles (ZnO NPs) were fabricated using the crustacean immune molecule β-1, 3- glucan binding protein (Phβ-GBP, 100kDa) purified from the heamolymph of Paratelphusa hydrodromus. β-GBP coated zinc oxide nanoparticles (Phβ-GBP-ZnO NPs) were characterized by UV-vis spectroscopy, X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), and high resolution-transmission electron microscopy (HR-TEM) analyses. Phβ-GBP-ZnO NPs inhibited the growth of Staphylococcus aureus and Proteus vulgaris. Protein and nucleic acid leakage assays showed that Phβ-GBP-ZnO NPs facilitate membrane permeability leading to cell death. The antibacterial activity of Phβ-GBP-ZnO NPs was due to the high level of reactive oxygen species (ROS) release from bacterial cells post-treatment with 75μg/mL of Phβ-GBP-ZnO NPs. Confocal laser scanning microscopy pointed out that biofilm thickness was highly reduced post-treatment with nanoparticles. Cytotoxicity on human liver carcinoma (HepG2) cells highlighted that 75μg/mL of Phβ-GBP-ZnO NPs inhibited viability of HepG2 cells. Phase contrast microscopy showed key morphological changes of HepG2 cells post-treatment with Phβ-GBP-ZnO NPs. Overall, Phβ-GBP-ZnO NPs can be further considered for the development of novel drugs against microbial pathogens and HepG2 cells.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibiofilm; Cytotoxicity; Paratelphusa hydrodromus; Protein leakage; Zinc oxide nanoparticles

Mesh:

Substances:

Year:  2017        PMID: 28704712     DOI: 10.1016/j.colsurfb.2017.06.035

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  6 in total

Review 1.  ZnO nanostructured materials and their potential applications: progress, challenges and perspectives.

Authors:  Sauvik Raha; Md Ahmaruzzaman
Journal:  Nanoscale Adv       Date:  2022-03-09

2.  Green synthesis of ZnO nanoparticles for antimicrobial and vegetative growth applications: A novel approach for advancing efficient high quality health care to human wellbeing.

Authors:  Saraswathi Umavathi; Shahid Mahboob; Marimuthu Govindarajan; Khalid A Al-Ghanim; Zubair Ahmed; P Virik; Norah Al-Mulhm; Murugesh Subash; Kasi Gopinath; C Kavitha
Journal:  Saudi J Biol Sci       Date:  2020-12-19       Impact factor: 4.219

Review 3.  Impact of nanosystems in Staphylococcus aureus biofilms treatment.

Authors:  Rita M Pinto; Daniela Lopes-de-Campos; M Cristina L Martins; Patrick Van Dijck; Cláudia Nunes; Salette Reis
Journal:  FEMS Microbiol Rev       Date:  2019-11-01       Impact factor: 16.408

4.  Development of bactericidal spinel ferrite nanoparticles with effective biocompatibility for potential wound healing applications.

Authors:  Atiya Rabbani; Reihaneh Haghniaz; Taous Khan; Romana Khan; Ayesha Khalid; Syeda Sohaila Naz; Mazhar Ul-Islam; Fereshteh Vajhadin; Fazli Wahid
Journal:  RSC Adv       Date:  2021-01-06       Impact factor: 3.361

5.  Enhanced Activity and Sustained Release of Protocatechuic Acid, a Natural Antibacterial Agent, from Hybrid Nanoformulations with Zinc Oxide Nanoparticles.

Authors:  Khaled AbouAitah; Urszula Piotrowska; Jacek Wojnarowicz; Anna Swiderska-Sroda; Ahmed H H El-Desoky; Witold Lojkowski
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

Review 6.  The Advancing of Zinc Oxide Nanoparticles for Biomedical Applications.

Authors:  Jinhuan Jiang; Jiang Pi; Jiye Cai
Journal:  Bioinorg Chem Appl       Date:  2018-07-05       Impact factor: 7.778

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.